AstraZeneca: Lynparza shows results in ovarian cancer trial

(CercleFinance.com) - Treatment of advanced ovarian cancer with AstraZeneca and Merck's Lynparza increased the patients' median survival without disease progression or death, according to phase III data.


Progression-free survival was significantly increased in the Lynparza arm (13.4 months), compared to the chemotherapy arm (9.2 months), the companies said.

The trial's results also showed a statistically-significant and clinically-meaningful improvement in objective response rate in the Lynparza arm (72%), compared to the chemotherapy arm (51%).

Lynparza is being jointly developed and commercialized by AstraZeneca and Merck.

Copyright (c) 2019 CercleFinance.com. All rights reserved.